Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
04 September 2019 | Story Leonie Bolleurs | Photo Charl Devenish
Jon Jacobson
Delivering the 31st Sophia Gray Memorial Lecture and Exhibition in Bloemfontein, was Jon Jacobson from Metropolis Design in Cape Town.

What is inside and what is outside? What is coming alive in the light? Minimalism. Hugeness. Shadows. Soft. Art. Complex. Conversation. Ambiguity. Clarity. All phrases and words used by the most recent Sophia Gray laureate, Jon Jacobson from Metropolis Design in Cape Town, to describe aspects of his work.

He delivered the 31st Sophia Gray memorial lecture in Bloemfontein. The name of his lecture at this prestigious event, organised by the UUFS Department of Architecture, was in [de] finite. Jacobson is the first graduate in the department’s MArch with Design.

Nature plays a big role in many of his projects, with a blurred distinction between the inside and the outside of the structures he builds. His designs fulfil the desire of a union with nature. 

A detailed investigation

Jacobson creates places and spaces to celebrate being. “Architecture is undeniably art, but it is also embodied in the completeness of the lived moment,” he says. 

Every project starts with a detailed investigation. “What social theory will we engage with? How progressive is it? What attitude will we take to the environment, to the theory of family? What other personal concerns will we be worried about? It is important to engage critically with this information. Important to build a philosophical base for each project,” says Jacobson.

He also believes it is important to consciously ensure that form follows idea with the same intensity that it follows function and that it does not blindly follow other form. 

At Metropolis, Jon and his team are client centred in their approach to design. Jon explains the process: “Some of the content is brought from the client’s personal and social aspiration and some from contemporary architecture culture, but the most potent component is the hidden set of ideas that emerge from our own engagements with the living world such as popular science, geology, art, music, literature, philosophy, theology, mysticism, and many others. And this emerges in the hidden sense of the word, in its architecture content.”

Content approach to design

In house design, Jon categorises the content that informs the architecture of the house: content pertaining to the individual, their philosophy, values and beliefs, content derived from culture, architecture and the arts, passion, religion, politics, and content referring to the natural world and its processes. Content from each of these spheres is present in any of his work. 

Jon says a major implication of a content approach to design is that it requires a design framework that is largely operative at a level of idea rather than at the level of form. This contributes to creating architecture rather than just buildings. 

His design method allows conscious control over the relationship between the ideas, the forms, and the poetics of the projects. “And at any point in the building process, it is possible to trace back and to critically assess whether any particular form is aligning with the core ideas of the project,” Jon indicates. 

Jon’s first taste of grappling with the infinite of architecture was with a garden pavilion he built for rest and relaxation. “For the first time I felt that we integrated planning, content, sight, programme, structure, and materiality into one unified whole that was expressed with a minimum of means and that was more than just the sum of its part,” he states.

He strongly believes that the individual is at the centre of every architectural project. He says the belief systems, type of social needs, family dynamics, physical habits, and spatial practices of their clients need to be investigated in detail in order to facilitate a meaningful spatial experience.

He continues: “We see our role as designers to saturate the environment with the meaning that enhances our clients’ daily experience in every possible way – from the ergonomic and the practical to the spiritual. In the process, the logics and tradition of architecture and the ego of the architect sometimes need to make way for human need and aspiration.”


News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept